



# AIM Global Health Care Fund

## Sectors

Data as of Dec. 31, 2009

### Investment objective and strategy

The fund seeks long-term growth of capital by investing in equity securities of health care companies throughout the world.

### Portfolio management

Derek Taner, Dean Dillard

### How does the fund fit into your portfolio?

- **Satellite position.** The fund is a sector-oriented product that can be added as a satellite position to enhance return potential when used in a strategic or tactical allocation.
- **Contrarian investment approach.** Fund management seeks to invest in equity securities of undervalued health care companies with the potential to appreciate as the companies become more fully valued and realize their growth potential.
- **Sector coverage.** The fund provides exposure to various industries within the health care sector, which may include both domestic and international companies, including biotechnology, pharmaceuticals, health care facilities, health care services and health care equipment.


### Investment Results

Average Annual Total Returns (%)							as of Dec. 31, 2009
Period	Class A Shares Inception: 08/07/89		Class C Shares Inception: 03/01/99		Investor Class Shares Inception: 07/15/05	Class Y Shares Inception: 10/03/08	Style-Specific Index
	Max Load 5.50%	NAV	Max CDSC 1.00%	NAV	NAV	NAV	MSCI World Health Care Index
Inception	10.05	10.35	5.94	5.94	-	-	-
20 Years	9.79	10.10	-	-	-	-	-
15 Years	9.82	10.23	-	-	-	-	-
10 Years	5.94	6.54	5.89	5.89	6.55	6.58	2.92
5 Years	1.76	2.92	2.17	2.17	2.93	2.98	3.16
3 Years	-1.28	0.60	-0.14	-0.14	0.60	0.71	-1.01
1 Year	20.43	27.46	25.53	26.53	27.44	27.79	18.89
Quarter	0.63	6.51	5.32	6.32	6.50	6.58	7.40

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Visit [invescoaim.com](http://invescoaim.com) for the most recent month-end performance. Performance figures reflect reinvested distributions and changes in net asset value (NAV). Investment return and principal value will vary so that you may have a gain or a loss when you sell shares. No contingent deferred sales charge (CDSC) will be imposed on redemptions of Class C shares following one year from the date shares were purchased. Performance shown at NAV does not include applicable CDSC or front-end sales charges, which would have reduced the performance. Investor Class shares have no sales charge; therefore, performance is at NAV. Returns since the Investor Class shares' inception date are historical returns. All other returns are blended returns of historical Investor Class share performance and restated Class A share performance (for periods prior to the inception date of Investor Class shares) at NAV and reflect the Rule 12b-1 fees applicable to Class A shares. Class Y shares have no sales charge; therefore, performance is at NAV. Returns since the Class Y shares' inception date are actual returns. All other returns are blended returns of actual Class Y share performance and restated Class A share performance (for periods prior to the inception date of Class Y shares) at NAV and reflect the Rule 12b-1 fees as well as any fee waivers or expense reimbursements applicable to Class A shares. A 2% redemption fee will be imposed on certain redemptions or exchanges out of the fund within 31 days of purchase. Exceptions to the redemption fee are listed in the fund's prospectus. Returns less than one year are cumulative; all other performance figures are annualized.

Index source: Lipper Inc.

### Calendar-Year Total Returns (%)



### About risk

The values of convertible securities in which the fund invests may be affected by market interest rates, the risk that the issuer may default on interest or principal payments, and the value of the underlying common stock into which these securities may be converted.


Investing in developing countries can add additional risk, such as high rates of inflation or sharply devalued currencies against the U.S. dollar. Transaction costs are often higher, and there may be delays in settlement procedures.

Prices of equity securities change in response to many factors, including the historical and prospective earnings

### Fund Facts

Nasdaq	A: GGHCX B: GTHBX C: GTHCX Investor: GTHX Y: GGHYX
Total Net Assets	\$1,041,732,334
Total Number of Holdings	73
Annual Turnover (as of 10/31/09)	61%

### Investment Map(s)



The map illustrates areas in which the fund typically invests, not necessarily within a limited period of time. This fund is not classified with regard to one primary market capitalization.

### Top Equity Holdings

Company	% of Total Net Assets
Roche Holding Ltd.	4.38
Gilead Sciences Inc.	4.28
Thermo Fisher Scientific Inc.	3.95
Amgen Inc.	3.82
Abbott Laboratories	3.42
CVS Caremark Corp.	3.20
Johnson & Johnson	2.59
Boston Scientific Corp.	2.58
WellPoint Inc.	2.52
Baxter International Inc.	2.51

Holdings are subject to change and are not buy/sell recommendations.

### Top Countries

Country	% of Total Net Assets
United States	76.53
Switzerland	6.14
Germany	4.98
Ireland	2.42
Brazil	2.35
United Kingdom	2.25
Australia	1.19
France	1.13
Israel	1.12
Russia	0.27

Holdings are subject to change and are not buy/sell recommendations.

### Expense Ratios

Class	% Net	% Total
Class A Shares	1.22	1.23
Class C Shares	1.97	1.98
Investor Class Shares	1.22	1.23
Class Y Shares	0.97	0.98

Per the current prospectus

Net = Total annual operating expenses less any contractual fee waivers and/or expense reimbursements by the adviser in effect through at least June 30, 2010. See current prospectus for more information.

## About risk (continued)

of the issuer, the value of its assets, general economic conditions, interest rates, investor perceptions and market liquidity.

Foreign securities have additional risks, including exchange rate changes, political and economic upheaval, relative lack of information, relatively low market liquidity, and the potential lack of strict financial and accounting controls and standards.

The value of the fund's shares is particularly vulnerable to factors affecting the health care industry, such as substantial government regulation that may affect the demand for products and services offered by health care companies. Also, the products and services offered by health care companies may be subject to rapid obsolescence caused by scientific advances and technological innovations, which can cause fund shares to rise and fall more than the value of shares of a fund that invests more broadly.

The prices of securities held by the fund may decline in response to market risks.

The fund invests in synthetic instruments, the value of which may not correlate perfectly with the overall securities markets. Rising interest rates and market price fluctuations will affect the performance of the fund's investments in synthetic instruments.

Investor Class shares are closed to new investors. Investors should contact their financial adviser about other share classes.

Class Y shares are available only to certain investors. See the prospectus for more information.

The fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

The MSCI World Health Care Index is an unmanaged index considered representative of health care stocks of developed countries. An investment cannot be made directly in an index.

**12-month forward and trailing P/E** are calculated using weighted harmonic averaging, which helps avoid extreme results that may occur due to small relative numbers in the denominator. It doesn't exclude extreme values; instead, it reduces the effect of outliers on the aggregate calculation. The **price/book ratio** is the market price of a stock divided by the book value per share.

**Return on equity (ROE)** is net income divided by net worth. The **three-year EPS growth rate** is a weighted average of each stock holding's growth rate in earnings per share (EPS). EPS is total earnings divided by the number of shares outstanding. The **five-year dividend growth rate** is the weighted average of each stock holding's annualized percentage rate of growth in dividend yield over five years. **Alpha** (cash adjusted) is a measure of performance on a risk-adjusted basis. **Beta** (cash adjusted) is a measure of relative risk and the slope of regression. **R-squared** (cash adjusted) expresses the proportion of variation in the return of one fund explained by the return of a benchmark. **Tracking error** measures the difference between returns of a portfolio and its benchmark index. The **up and down capture** measures how well a manager was able to replicate or improve on periods of positive benchmark returns and how severely the manager was affected by periods of negative benchmark returns. **Standard deviation** measures a fund's range of total returns and identifies the spread of a fund's short-term fluctuations.

All data provided by Invesco unless otherwise noted.

## External Comparisons

### Morningstar Ratings and Rankings and Lipper Rankings

Class A Shares as of Dec. 31, 2009

	Overall	1 Year	3 Years	5 Years	10 Years
vs. Morningstar Health Category*					
A Shares (Load)	★★★★	N/A	★★★★	★★	★★★★
A Shares (Load Waived)	★★★★	N/A	★★★★	★★★★	★★★★
Number of Funds in Category	157	N/A	157	143	68
vs. Morningstar Health Category**		20%	51%	58%	37%
		(33 of 165)	(80 of 157)	(83 of 143)	(26 of 68)
vs. Lipper Global Health/Biotechnology Funds Category***		9%	36%	57%	32%
		(4 of 45)	(15 of 41)	(21 of 36)	(6 of 18)

\*Source: ©2010 Morningstar Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Ratings are based on a risk-adjusted return measure that accounts for variation in a fund's monthly performance, placing more emphasis on the downward variations and rewarding consistent performance. With-load ratings include the effect of sales charges, loads and redemption fees. Load-waived ratings exclude sales charges, loads and redemption fees, and are only applicable to investors not subject to sales charges. The overall rating is derived from a weighted average of three-, five- and 10-year rating metrics, as applicable. Ratings are as of the most recent quarter end and are subject to change every month. A fund is eligible for a Morningstar rating three years after inception. The top 10% of funds in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) Ratings for other share classes may differ due to different performance characteristics. Past performance does not guarantee future results.

\*\*Source: Morningstar Inc. Morningstar rankings are based on total return, excluding sales charges and including fees and expenses, versus all funds in the category tracked by Morningstar.

\*\*\*Source: Lipper Inc. Lipper fund percentile rankings are based on total returns, excluding sales charges and including fees and expenses, and are versus all funds in the category tracked by Lipper.

### Portfolio Characteristics: Fund vs. MSCI World Health Care Index

#### Valuation Statistics

	Fund	Index
12-Month Forward P/E	15.65	11.69
12-Month Trailing P/E	18.21	12.68
Price/Book LTM (Wtd. Avg.)	3.73	3.69
1-Year ROE (Wtd. Avg.)	14.62	20.46
12-Month Fwd. Growth Rate (Median) (%)	12.81	12.03
3-Year EPS Growth Rate (Wtd. Avg.) (%)	13.76	11.20
5-Year Dividend Growth Rate (Wtd. Avg.) (%)	15.05	13.61
Weighted Average Market Cap (\$MM)	32,321	72,556
Weighted Median Market Cap (\$MM)	16,749	57,475
3-Year Standard Deviation	17.09	16.41

Sources: Invesco, Compustat, Thomson Financial, MSCI, StyleADVISOR

#### Statistics

Fund vs. Index	3 Years	5 Years
Alpha (%)	1.74	-0.05
Beta	0.98	0.96
R-Squared	0.89	0.83
Tracking Error (%)	5.77	5.92
Up Capture (%)	109.43	107.20
Down Capture (%)	100.18	107.06

Source: StyleADVISOR; based on Class A shares

#### Asset Mix (%)

	at 12/31/09	at 12/31/08
Domestic Common Stock	76.37	77.52
International Common Stock	22.02	17.12
Cash	1.33	5.59
Domestic Preferred Stock	0.15	0.18
Other	0.11	-0.43
Domestic Convertible Preferred Stock	0.02	0.02

#### Equity Sector Breakdown

Market Sector	Fund	Index
Health Care	93.03	100.00
Consumer Staples	4.53	0.00
Financials	1.04	0.00
Consumer Discretionary	0.00	0.00
Energy	0.00	0.00
Industrials	0.00	0.00
Information Technology	0.00	0.00
Materials	0.00	0.00
Telecommunication Services	0.00	0.00
Utilities	0.00	0.00

Sources: Invesco, MSCI

#### Capitalization Breakdown

	% of Equities	
	Fund	Index
Giant	24.17	59.15
Large	41.72	28.58
Mid	24.56	12.27
Small	8.77	0.00
Micro	0.78	0.00

Based on Morningstar capitalization ranges

#### Geographic Diversification

Region	% of Total Net Assets
Europe	17.23
Asia	1.20
Latin America	2.37
Africa/Middle East	1.27
North America	76.53

Developed Market Exposure	94.69
Emerging Markets Exposure	3.91

## NOT FDIC INSURED | MAY LOSE VALUE | NO BANK GUARANTEE

Consider the investment objectives, risks, and charges and expenses carefully. For this and other information about AIM funds, obtain a prospectus from your financial adviser and read it carefully before investing.

Note: Not all products, materials or services available at all firms. Advisers, please contact your home office.

# AIM Global Health Care Fund

Data as of Dec. 31, 2009

## Performance summary

- AIM Global Health Care Fund underperformed the MSCI World Health Care Index for the fourth quarter. (Please see the returns table on page 1 for fund and index performance.)
- The U.S. economy provided signs of continued improvement during the fourth quarter, offering indications that the economy has transitioned from a contraction phase into an expansionary phase. Nevertheless, the pace of the recovery remains relatively modest, and the transition from government stimulus-induced growth to a private economic recovery is uncertain. While the labor markets have improved as layoffs have moderated, significant capacity persists and new hiring remains quite weak.
- Following the improvement in many economic indicators, most equity markets trended higher during the quarter. However, rising interest rates remain a potential headwind to future economic growth.
- Health care was among the better performing market sectors during the fourth quarter, lagging behind only information technology (IT) stocks.
- The fund delivered strong returns, but lagged its style benchmark due to an overweight exposure in biotechnology and drug retail stocks. Security selection and an underweight exposure to pharmaceuticals also hurt relative performance.

## Contributors to performance

- On an absolute basis, managed care, pharmaceuticals and health care equipment stocks contributed the most to the fund's performance.
- Relative to the index, our security selection and overweight exposure in managed health care, and our security selection in the life sciences tools and services industry were beneficial during the fourth quarter.
- The cumulative result of our currency hedges also positively affected our benchmark-relative performance.
- Managed health care companies, in general, benefited from increased clarity on health care reform efforts. As a result, our overweight to the industry, and two stocks in particular, aided fund performance. **Health Net Inc.** and **WellPoint Inc.** (1.58% and 2.52% of total net assets, respectively) were the top contributors to fund performance.

## Detractors from performance

- Biotechnology and drug retail stocks detracted from both the fund's absolute and relative performance during the fourth quarter. Security selection and an underweight exposure to pharmaceuticals also hurt relative performance.
- Within drug retail, **CVS/Caremark Corp.** (3.20% of total net assets) detracted from the fund's quarterly performance after it announced disappointing earnings guidance for 2010. We believe the company offers high visibility earnings growth over the next few years and will be a beneficiary of the looming patent expiration cycle. Also, the stock continued to trade at a significant discount to industry peers at the close of the quarter.
- **Genzyme Corp.** (1.90% of total net assets), in addition to suffering from the headwinds of the rotation out of large-cap biotechnology stocks, was also negatively affected by drug manufacturing issues. As a result, **Genzyme** detracted from fund performance but remained a large position in the portfolio given its favorable long-term prospects.

## Top contributors and detractors

Contributors	(%) of Total Assets	Detractors	(%) of Total Assets
1. Health Net Inc.	1.58	1. CVS/Caremark Corp.	3.20
2. WellPoint Inc.	2.52	2. Genzyme Corp.	1.90
3. Alcon Inc.	2.13	3. Gilead Sciences Inc.	4.28
4. Thermo Fisher Scientific Inc.	3.95	4. Amgen Inc.	3.82
5. Abbott Laboratories	3.42	5. Rhoen-Klinikum	2.01

## Positioning and outlook

- Over the past year, we have steadily reduced the number of fund holdings to between 50 to 80 stocks in order to make the fund more concentrated.
- Massive health care reform seems unlikely in the near term, and we think a watered-down version of the current proposal is more likely.
- Most importantly, not all health care companies would be affected by health care reform in the same way. Certainly, some industries, like health care equipment and biotechnology, are less exposed. As a result, we continued to overweight these industries.
- We continued to favor specialty pharmaceuticals and large-cap biotechnology stocks over large-cap pharmaceuticals. Relative to the benchmark, we maintained a significant underweight in large-cap pharmaceuticals, as many firms face looming patent expirations with limited drug pipelines, which may result in modest (if any) earnings growth.
- Our emphasis on specialty pharmaceuticals and biotechnology stocks was based on robust in-line portfolios, compelling pipelines and the view that many of these companies could be targets of ongoing consolidation. Importantly, the valuations for many of these companies were near historic lows.
- We continued to focus on companies with new product cycles, less reimbursement risk and less competition. The majority of the fund is invested in domestic stocks, where more companies fit our fundamental selection criteria. Our international weight was focused mainly on European large-cap pharmaceutical companies with fewer patent expiration concerns.
- Health care trades at a 30% discount to the market, which is relatively the cheapest it has been since the mid-1990s. Catalysts include some clarity on health care reform, which should spur future growth as the government spends more on health care.
- Another potential catalyst is the first sign that the U.S. Federal Reserve will raise rates. Health care typically performs well relative to the market when rates rise.
- Equity markets experienced a strong recovery during 2009. We would like to caution investors against making investment decisions based on short-term performance. As always, we recommend that you consult a financial adviser to discuss your individual financial program.

Opinions expressed are those of the fund's portfolio management.